# Mesoblast

Mesoblast is an Asset Manager based in Melbourne, Australia.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Melbourne, Australia
- **Region:** Oceania
- **Address:** Melbourne, Australia
- **Founded:** 2004
- **Assets under management:** Undisclosed
- **Website:** mesoblast.com

## Regulatory record

- **Reports private funds:** No

## About

Mesoblast was established in 2004 by Silviu Itescu, a physician-scientist with a background in immunology and stem cell biology. The Australian-founded company operates as a developer of allogeneic cellular medicines based on its proprietary mesenchymal lineage cell platform, targeting serious and life-threatening inflammatory conditions. Its structure as an ASX- and Nasdaq-listed operating company distinguishes it from the pooled investment vehicles typically profiled by allocators. The company's lead candidate, remestemcel-L, has been developed for inflammatory conditions including pediatric steroid-refractory acute graft versus host disease and moderate to severe acute respiratory distress syndrome. Its technology platform isolates and expands specific cellular subpopulations with immunomodulatory properties. The firm cut manufacturing operations in Singapore to supply late-stage clinical trials and potential commercial launch. Mesoblast's pipeline also includes rexlemestrocel-L for chronic low back pain due to disc degeneration and chronic heart failure, with phase 3 programs completed or ongoing. Mesoblast maintains headquarters in Melbourne, Australia, with operational presence in New York and a manufacturing facility in Singapore. As of March 2024, the US Food and Drug Administration informed the company that its resubmitted Biologics License Application for remestemcel-L in pediatric steroid-refractory acute graft versus host disease had been accepted for review, with a Prescription Drug User Fee Act goal date of August 2, 2024 (per FDA correspondence, March 2024). The firm has previously secured strategic partnerships with pharmaceutical companies including Takeda and JCR Pharmaceuticals. Unlike an investment management firm, Mesoblast directs capital into regulated drug development rather than portfolio companies or funds. Its operational structure and public listing subject it to continuous disclosure requirements under Australian and US securities law, making its financial position and clinical milestones directly observable in a way that private capital allocators rarely encounter.

## Sectors

- Digital Health

## Offices

- New York, NY, United States
- Singapore

## People

- Silviu Itescu — Chief Executive Officer

## Questions

### Who runs investment decisions at Mesoblast?

Mesoblast does not make investment decisions in the allocator sense. Capital allocation focuses on advancing its own clinical pipeline and manufacturing capabilities, with Silviu Itescu as CEO and the board overseeing strategic deployment of corporate resources. The firm's cash position and burn rate are publicly reported.

### What is Mesoblast's core technology platform?

The proprietary platform isolates and culture-expands mesenchymal lineage cells with specific immunomodulatory properties. These allogeneic cells are sourced from healthy adult donor bone marrow and administered without the need for HLA matching between donor and recipient.

### What is Mesoblast's known posture on co-investments alongside external GPs?

Mesoblast does not co-invest alongside external general partners or participate in fund commitments. The company is a publicly traded commercial-stage biopharmaceutical developer, not a limited partner.

## Related profiles

- [Idaho Copper Corp](https://altss.com/profile/idaho-copper-corp)
- [Ascentage Pharma Group International](https://altss.com/profile/ascentage-pharma-group-international)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/mesoblast-ltd

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology